BridgeBio Pharma Gross Margin Growth & History (BBIO)

BridgeBio Pharma's gross margin was 95.82% for fiscal 2025.

View full BridgeBio Pharma company overview

BridgeBio Pharma annual gross margin history

BridgeBio Pharma annual gross margin

Fiscal yearPeriod endedGross marginChange (percentage points)
20252025-12-3195.82%−2.43 pp
20242024-12-3198.25%+24.54 pp
20232023-12-3173.71%−21.87 pp
20222022-12-3195.58%+0.04 pp
20212021-12-3195.53%

BridgeBio Pharma gross margin trends

Between the periods ended 2021-12-31 and 2025-12-31, BridgeBio Pharma's gross margin increased from 95.53% to 95.82%, a change of +0.29 percentage points. The latest reported quarter, Q2 2026, shows 93.83%.

About the metric

What gross margin means

Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.

Calculation and source

How gross margin is calculated

TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review BridgeBio Pharma source filings ↗

Community posts

It’s quiet here.

No posts about BBIO yet. Start the conversation.

Write the first post